Malignant mesothelioma is a rare tumour that arises from the mesothelial surfaces of the pleura, peritoneum, pericardium, or the tunica vaginalis, with the pleura the most commonly affected site. By 2015, mesothelioma is expected to result in approximately 2,000 deaths per annum in the UK. In the US, there are approximately 3,000 cases of malignant mesothelioma diagnosed yearly. Mesothelioma historically carried a dismal prognosis but, with the advent of new treatment options and translational research, progress is being made. This article will address pleural mesothelioma.
Get full access to this article
View all access options for this article.
References
1.
Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Sculier JP.Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002 Nov;38(2):111–21.
2.
Bueno R, Reblando J, Glickman J, Jaklitsch MT, Lukanich JM, Sugarbaker DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 2004 Nov;78(5):1774–6.
3.
Gralla RJ, Hollen PJ, Liepa AM, Symanowski JT,Boyer MJ,Abraham R, Rusthoven JJ, Paz-Ares L,Vogelzang NJ. Improving quality of life in patients with malignant pleural mesothelioma: Results of the randomised pemetrexed + cisplatin vs. cisplatin trial using the LCSSmeso instrument. Proc Am Soc Clin Oncol 22: 2003 (abstr 2496).
4.
Marom EM, Erasmus JJ, Pass HI, Patz EF Jr. The role of imaging in malignant pleural mesothelioma. Semin Oncol 2002 Feb;29(1):26–35.
5.
O'Brien ME,Watkins D, Ryan C, Priest K, Corbishley C, Norton A, Ashley S, Rowell N, Sayer R. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.Ann Oncol 2006 Feb;17(2):270–5.
6.
Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P. Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006 May 15;173(10):1155–60. Epub 2006 Feb 2.
7.
McElvenny DM, Darnton AJ, Price MJ, Hodgson JT. Mesothelioma mortality in Great Britain from 1968 to 2001. Occup Med (Lond) 2005; 55(2):79–87.
8.
Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92(3):587–93.
9.
Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145(3):211–8.
10.
Jaurand MC, Fleury-Feith J. Pathogenesis of malignant pleural mesothelioma. Respirology 2005; 10(1):2–8.
11.
Gazdar AF, Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 2003; 5(3):177–81.
12.
Sugarbaker DJ, Norberto JJ, Bueno R. Current therapy for mesothelioma. Cancer Control 1997; 4(4):326–34.
13.
Berry G, Liddell FD. The interaction of asbestos and smoking in lung cancer: a modified measure of effect. Ann Occup Hyg 2004; 48(5):459–62.
14.
Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992; 34(7):718–21.
15.
Corson JM. Pathology of mesothelioma. Thorac Surg Clin 2004; 14(4):447–60.
16.
Johansson L, Linden CJ. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Chest 1996; 109(1):109–14.
17.
Ceresoli GL, Locati LD, Ferreri AJ Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001; 34(2):279–87.
18.
Bueno R, Reblando J, Glickman J Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 2004; 78(5):1774–6.
19.
Ordonez NG. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999; 30(3):313–23.
20.
Kushitani K, Takeshima Y, Amatya VJ Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 2007; 57(4):190–9.
21.
Attanoos RL, Dojcinov SD,Webb R, Gibbs AR. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000; 37(3):224–31.
22.
Lucas DR, Pass HI, Madan SK Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology 2003; 42(3):270–9.
23.
Robinson BW, Creaney J, Lake R Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362(9396):1612–6.
24.
Scherpereel A, Lee YG. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007; 13(4):339–443.
25.
Grigoriu BD, Scherpereel A, Devos P Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13(10):2928–35.
26.
Scherpereel A, Grigoriu B, Conti M Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173(10):1155–60.
27.
Marom EM, Erasmus JJ, Pass HI, Patz EF Jr. The role of imaging in malignant pleural mesothelioma. Semin Oncol 2002; 29(1):26–35.
28.
Heelan RT, Rusch VW, Begg CB Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999; 172(4):1039–47.
29.
Maziak DE, Gagliardi A, Haynes AE, Mackay JA, Evans WK. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005; 48(2):157–69.
30.
Treasure T, Tan C, Lang-Lazdunski L,Waller D. The MARS trial: mesothelioma and radical surgery. Interact Cardiovasc Thorac Surg 2006; 5(1):58–9.
31.
Sugarbaker DJ, Flores RM, Jaklitsch M Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117(1):54–63.
32.
Van Ruth S, Baas P, Zoetmulder FA. Surgical treatment of malignant pleural mesothelioma: a review. Chest 2003; 123(2):551–61.
33.
Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995;107(5):1454–6.
34.
Stevens CW, Forster KM, Smythe WR, Rice D. Radiotherapy for mesothelioma. Hematol Oncol Clin North Am 2005; 19(6):1099–115.
35.
Senan S. Indications and limitations of radiotherapy in malignant pleural mesothelioma. Curr Opin Oncol 2003; 15(2):144–7.
36.
Ahamad A, Stevens CW, Smythe WR Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 2003; 9(6):476–84.
37.
Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995; 107(6 Suppl):332S–344S.
38.
Berghmans T, Paesmans M, Lalami Y Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38(2):111–21.
39.
Vogelzang NJ, Rusthoven JJ, Symanowski J Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21(14):2636–44.
40.
Girling DJ, Muers MF, Qian W, Lobban D. Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council. Semin Oncol 2002; 29(1):97–101.
41.
Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005; 10(3):266–83.
42.
Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006; 1(6):591–601.
43.
Qua JC, Rao UN, Takita H. Malignant pleural mesothelioma: a clinicopathological study. J Surg Oncol 1993; 54(1):47–50.
44.
Waite K, Gilligan D. The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clin Oncol (R Coll Radiol) 2007; 19(3):182–7.
45.
O’Brien ME, Watkins D, Ryan C A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006; 17(2):270–5.
